Tamoxifen alters dopamine output through direct actions upon superfused corpus striatal tissue fragments

Neurochemistry International

Volumn 32, Issue 3, 1998, Pages 299-307

  McDermott, Janet L ^a,b   Anderson, Linda I ^b   Dluzen, Dean E ^b  

^a Edwin Shaw Hospital   (United States)

^b NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Anti estrogen; Breast cancer; Estrogen; Nigrostriatal; Non genomic

Indexed keywords

CALCIUM ION; DOPAMINE; TAMOXIFEN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DRUG INFUSION; DRUG MECHANISM; FEMALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ANIMALS; CALCIUM; CORPUS STRIATUM; CULTURE TECHNIQUES; DIFFUSION CHAMBERS, CULTURE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; OVARIECTOMY; PERFUSION; RATS; RATS, SPRAGUE-DAWLEY; TAMOXIFEN; TIME FACTORS;

ANIMALIA;

EID: 0032033518     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-0186(97)00086-7     Document Type: Article

References (51)

1. Baksi, S. N., Redington, T. E., & Hughes, M. J. (1981). Antiestrogen-induced alterations of hypothalamic dopamine and norepinephrine levels in the female rat. Neuropharmacology, 20, 1163-1167.
2. Baksi, S. N., Hughes, M. J., & Light, K. E. (1985). Alterations of dopamine metabolism in different brain regions of the rabbit by estradiol and tamoxifen. Neuroscience, 14, 1053-1059.
3. Barber, P. V., Arnold, A. G., & Evans, G. (1976). Recurrent hormone dependent chorea: Effects of oestrogens and progesterones. Clin. Endo., 5, 291-293.
4. Becker, J. B. (1990). Direct effect of 17β-estradiol on striatum: Sex differences in dopamine release. Synapse, 5, 157-164.
5. Bedard, P., Langelier, P., & Villeneuve, A. (1977). Oestrogens and extrapyramidal system. Lancet, 2, 1367-1368.
6. Berthois, Y., Pons, M., Dussert, C., Crastes de Paulet, A., & Martin, P.-M. (1994). Agonist-antagonist activity of anti-estrogens in the human breast cancer cell line MCF-7: an hypothesis for the interaction with a site distinct from the estrogen binding site. Molec. Cell. Endo., 99, 259-268.
7. Bixo, M., Backstrom, T., Winblad, B., Selstam, G., & Anderson, A. (1986). Comparison between pre- and post-ovulatory distributions of oestradiol and progesterone in the brain of the PMSG-treated rat. Acta Physiol. Scand., 128, 241-246.
8. Cancer Research Campaign Breast Cancer Trials Group. (1992). The effect of adjuvant tamoxifen: The latest results from the cancer research campaign adjuvant breast trial. Eur. J. Cancer, 28A, 904-907.
9. Catherino, W. H., & Jordan, V. C. (1995). Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analog. Can. Lett., 92, 39-47.
10. Cuzick, J., Allen, D., Baum, M., Barrett, J., Clark, G., Kakkan, V., Melissari, E., Moniz, C., Moore, J., Parsons, V., Pemberton, K., Pitt, P., Richmond, W., Houghton, J., & Riley, D. (1993). Long term effects of tamoxifen. Eur. J. Cancer, 29A, 15-21.
11. + evoked dopamine release from superfused corpus striatal tissue fragments. Brain Research, 764, 9-16.
12. Dluzen, D. E., & Kratko, Jr. F. T. (1992). L-DOPA infusion mode differentially affects corpus striatal dopamine efflux in the presence of reserpine. J. Neural Transm. [Gen. Sect.], 89, 197-207.
13. Dluzen, D. E., & Ramirez, V. D. (1987). Daily changes in vitro spontaneous dopamine efflux from the corpus striatum of male rats. Chronobiol. Int., 4, 417-482.
14. Etgen, A. E. (1979). Antiestrogens: Effects of tamoxifen. nafoxidine and Cl-628 on sexual behavior, cytoplasmic receptors and nuclear binding of estrogen. Horm. Behav., 13, 97-112.
15. Fanidi, A., Courion-Guichardaz, C., Fayard, J.-M., Pageaux, J.-F., & Laugier, C. (1989). Effects of tamoxifen, tamoxifen metabolites and nafoxidine on cAMP phosphodiesterase: Correlations with growth inhibitory activities but not estrogen receptor affinities. Endocrinology, 125, 1187-1193.
16. Gamboa, L. T., Isaacs, G., & Harter, D. H. (1971). Chorea associated with oral contraceptive therapy. Arch. Neurol., 25, 112-114.
17. Glazer, W. M., Naftolin, F., Morgenstern, H., Barnea, H. R., MacLusky, N. J., & Brenner, L. M. (1985). Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology, 10, 345-350.
18. Hansen, S. B., Galsgard, H., von Eyben, F., Westergaard-Nielsen, V., & Wolf-Jensen, J. (1986). Tamoxifen for brain metastases from breast cancer. Ann. Neurol., 20, 544.
19. Higa, G. M. (1994). Tamoxifen: 25 year perspective. Am. J. Hosp. Pharm., 51, 400-403.
20. Hiemke, C., & Ghraf, R. (1984). Interaction of non-steroidal antiestrogens with dopamine binding. J. Steroid Biochem., 21, 663-667.
21. Jordan, V. C., & Murphy, C. S. (1990). Endocrine pharmacology of antiestrogens as antitumor agents. Endo. Rev., 11, 578-610.
22. Kangas, L. (1992). Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol., 31, 143-146.
23. Kayyali, R., Marriot, C., & Wiseman, H. (1994). Tamoxifen decreases drug efflux from liposomes: Relevance to its ability to reverse multidrug resistance in cancer cells? FEBS Lett., 344, 221-224.
24. Kittner, B., Brautigam, M., & Hesken, H. (1987). PC12 Cells: A model system for studying drug effects on dopamine synthesis and release. Arch. Int. Pharmacodyn., 286, 181-194.
25. Koller, W. C., Barr, A., & Biary, N. (1982). Estrogen treatment of dyskinetic disorders. Neurology, 32, 547-549.
26. Lam, H.-Y. P. (1984). Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem. Biophys. Res. Comm., 118, 27-32.
27. Lazier, C. B., & Bapat, B. V. (1988). Antiestrogen binding sites: general and comparative properties. J. Steroid Biochem., 31, 665-669.
28. Lien, E. A., Solheim, E., & Veland, P. M. (1991a). Distribution of tamoxifen and its metabolites in rat and human tissues during steady state treatment. Can. Res., 51, 4837-4844.
29. Lien, E. A., Wester, K., Lonning, P. E., Solheim, E., & Veland, P. M. (1991b). Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients. Br. J. Cancer, 63, 641-645.
30. Love, R. R., Leventhal, H., Easterling, D. V., & Nerenz, D. R. (1989). Side effects and emotional distress during cancer chemotherapy. Cancer, 63, 604-612.
31. Love, R. R., Cameron, L., Connell, B. L., & Leventhal, H. (1991). Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Intern. Med., 151, 1842-1847.
32. Malaab, S. A., Pollak, M. N., & Goodyer, C. G. (1992). Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur. J. Cancer, 28A, 788-793.
33. Marshall, E. (1994). Tamoxifen hanging in the balance. Science, 264, 1524-1527.
34. McDermott, J. L., Anderson, L. I., & Dluzen, D. E. (1997). Interactive effects of tamoxifen and estrogen upon the nigrostriatal dopaminergic system. Neuroendocrinology, 66. 181-187.
35. McDermott, J. L., Liu, B., & Dluzen, D. E. (1995). Tamoxifen treatment of ovariectomized mice alters dopamine release from striatal tissue fragments supervised in vitro. Brain Res., 698, 248-252.
36. McEwen, B. S., Coirini, H., & Schumacher, M., (1990). Steroid effects on neuronal activity: when is the genome involved? Ciba Fdn. Symp. Steroids and neuronal activity, 153, 3-21.
37. McKenna, S. E., Simon, N. G., & Cologer-Clifford, A. (1992). An assessment of agonist/antagonist effects of tamoxifen in the female mouse brain. Horm. Behav., 26, 536-544.
38. Meisel, R. L., Dohanich, G. P., McEwen, B. S., & Pfaff, D. W. (1987). Antagonism of sexual behavior in female rats by vent romedial hypothalamic implants of anti-estrogen. Neuroendocrinology, 45, 201-207.
39. Mermelstein, P. G., Becker, J. B., & Surmeier, D. J. (1996) Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci., 16, 595-604.
40. Morley, P., & Whitfield, J. F. (1994). Effect of tamoxifen on carbacholtriggered intracellular calcium responses in chicken granulosa cells. Cancer Res., 54, 69-74.
41. O'Brian, C. A., Liskamp, R. M., Solomon, D. H., & Weinstein, I. B. (1985). Inhibition of protein kinase C by tamoxifen. Cancer Res., 45, 2462-2465.
42. Pors, H., von Eyben, F. E., Sorenson, O. S., & Larsen, M. (1991). Long term remission of multiple brain metastases with tamoxifen. J. Neuro-Oncol., 10, 173-177.
43. Ramirez, V. D., Kim, K., & Dluzen, D. E. (1985). Progesterone action on the LHRH and nigrostriatal dopamine neuronal systems: In vitro and in vivo studies. Rev. Prog. Horm. Res., 41, 421-472.
44. Ron, I. G., Inbar, M. J., Barak, Y., Steir, S., & Chaitchik, S. (1992). Organic delusional syndrome associated with tamoxifen treatment. Cancer, 69, 1415-1417.
45. Toney, T. W., & Katzenellenbogen, B. S. (1987). An evaluation of the interactions of antiestrogens with pituitary and striata dopamine receptors. J. Recept. Res., 7, 695-712.
46. van den Koedijk, C. D. M. A., Blankenstein, M. A., & Thijssen, J. H. H. (1994). Speculations on the mechanisms of action of triphenylethylene antioestrogens. Biochem. Pharmacol., 47, 1927-1937.
47. van Hartesveldt. C., & Joyce, J. N. (1986). Effects of estrogen on the basal ganglia. Neurosci. Biobehav. Rev., 10, 1-14.
48. Wide, G. N., & Powers, J. B. (1993). Tamoxifen antagonizes the effects of estradiol on energy balance and estrous behavior in Syrian hamsters. Am. J. Physiol., 265, R559-R562.
49. Weiss, D. J., & Gurpide, E. (1988). Non-genomic effects of cstrogen and antiestrogens. J. Steroid Biochem., 31, 671-676.
50. 14C-labelled tamoxifen in spayed female mice. Acta Pharmacol. Toxicol., 50, 161-168.
51. Wiseman, H. (1994). Tamoxifen: New membrane mediated mechanisms of action and therapeutic advances. TiPS, 15, 83-89.